Obrindatamab

奥瑞达妥单抗

Report date: 2026/03/19 16:47:20

Base Information

Drug NameObrindatamab
Drug Alias NameOrlotamabMGD-009B7-H3 x CD3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD276 antigen inhibitorsT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsCD276 antigenT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S Oncology Group
Inactive CompaniesMacrogenics Inc
Active IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Synovial +[5] 
Inactive IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 

Other Information

ATC CodeN/A
Related LinksN/A